The Battle of Giants: Analyzing UnitedHealth Group vs. Humana Stocks

Analysis of Historical Performance

Stock performance paints a compelling narrative – while UNH showcases a robust 30% climb from $350 to around $460 since early 2021, HUM struggles, witnessing a steep 25% descent from $410 to approximately $310 over the same span. Interestingly, both UnitedHealth and Humana stumble in comparison to the S&P 500, registering a mere 40% collective upsurge within this three-year timeframe.

Observing the tumultuous trajectory of UNH and HUM stocks unveils a turbulent ride – UnitedHealth’s returns wavered at 43% in 2021, 6% in 2022, and plummeted by 1% in 2023. Conversely, Humana’s returns stumbled at 13%, followed by 10%, and a disheartening -11% in 2021, 2022, and 2023, respectively. Evidently, both stocks faltered against the S&P, showcasing a telling tale of market volatility.

Strikingly, consistently outperforming the S&P 500 emerges as an arduous feat for individual stocks in both flourishing and floundering market contexts. Noteworthy names in the healthcare arena alongside stalwarts like LLY, JNJ, and MRK, not to mention megacap luminaries GOOG, TSLA, and MSFT, find the S&P a formidable adversary. Conversely, the Trefis High Quality (HQ) Portfolio, boasting 30 select stocks, boasts a triumphant track record, comprehensively eclipsing the benchmark yearly. Why does this transpire? Uniting as a cohort, HQ Portfolio constituents yield superior returns with less exposure to risk, translating into a smoother investment journey, a paradigm tangible in HQ Portfolio’s financial performance metrics.

In light of the prevailing macroeconomic ambiguity rife with soaring oil prices and elevated interest rates, could UnitedHealth and Humana confront a predicament reminiscent of their 2023 woes and underperform the S&P over the ensuing 12 months? Or will a remarkable resurgence hallmark their fortunes? The crystal ball foresees an upward trajectory for both stocks, ushering in a phase of equilibrium proffering corresponding returns within the next triennium.

UnitedHealth’s Robust Revenue Growth

UnitedHealth eclipses Humana with its commendable revenue growth, boasting a 13% annual average escalation over the past three years, outstripping Humana’s 11%. In the last twelve months, both giants experienced a comparable 15% top-line expansion, albeit UnitedHealth emerges as the champion.

• UnitedHealth’s revenue ascent rides on the wave of burgeoning demand for its OptumHealth arm, furnishing healthcare services through local medical entities. Noteworthy is OptumHealth’s staggering 67% revenue uptick from 2020 to 2023, in stark contrast to the company’s overall 44% revenue upswing.
• The meteoric rise of OptumHealth credits a surge in patients benefiting from the company’s value-focused agreements, including domiciliary services.
• Contrarily, Humana’s zenith stems from swelling individual Medicare Advantage membership alongside amplified per-member medical premiums.
• Albeit Humana witnesses a modest uptick in its total medical member base, tallying 16.9 million currently versus 16.8 million in 2021, the strategic Enclara acquisition in 2020 bolsters Humana’s revenue momentum.
• Peruse our comprehensive ‘UnitedHealth Group Revenue Comparison’ and ‘Humana Revenue Comparison’ dashboards for detailed insights into both entities’ revenue spheres.
• Peering into the horizon unveils a mid-single-digit average annual revenue growth trajectory for both behemoths in the next three years.

The Yardstick of Profitability: UnitedHealth’s Dominance

• UnitedHealth’s unwavering operating margin of 8.7% in 2023, mirroring its 2020 level, dwarfs Humana’s descent from 6.5% to 3.8% over the same tenure.
• In the last twelve months, UnitedHealth’s 8.7% operating margin eclipses Humana’s 3.8%.
• The healthcare insurance sector grapples with escalating medical costs buoyed by a surge in elective procedures, bottling UnitedHealth’s operating margin expansion.
• A recent advisory from the U.S. Centers for Medicare & Medicaid Services citing a 3.7% uptick in Medicare Advantage payments in 2025, failing to meet market expectations, casts a shadow over UNH and HUM stocks, with potential ramifications on their profitability in the forthcoming fiscal year.
• Delving into financial risk exposes UnitedHealth’s fiscal fortitude – its meager 15% debt relative to equity pales in comparison to Humana’s substantial 32% burden. Further, UnitedHealth’s 11% cash relative to assets marginally edges out Humana’s 10%, painting UnitedHealth as the prominent player in debt and cash dynamics.

The Crux of the Matter

• UnitedHealth proves its mettle with superior revenue expansion, profitability, and a sturdy financial posture, evidenced in its elevated valuation compared to Humana.
• Based on P/S as a foundation for projections, we anticipate a parallel yield for both UnitedHealth and Humana within the next three years, attributable to pronounced oscillations in P/E and P/EBIT metrics.
• Per the Trefis Machine Learning analysis illuminating ‘Humana vs. UnitedHealth’, the forecast signifies a 15% upswing for UNH against a 16% ascent for HUM, underscoring analogous returns beckoning both entities.
• Comparing current valuation multiples against historical benchmarks paints a favorable picture for HUM, with UnitedHealth trading at 1.1x revenues, slightly beneath its five-year average of 1.4x. Conversely, Humana sits at 0.4x revenues, underpinning its historical average of 0.6x, signaling a potential uptick.
• Engage with our ‘UnitedHealth Group (UNH) Valuation Ratios Comparison’ and ‘Humana (HUM) Valuation Ratios Comparison’ for an in-depth exploration of valuation nuances.

As UnitedHealth and Humana set sail on the horizon with promises of similar returns in the offing, exploring ‘UnitedHealth Group’s Peers’ on pivotal metrics marks an insightful endeavor. Navigate through diverse comparative analyses spanning varied industries at ‘Peer Comparisons,’ enriching your investment acumen along the way.